Expertise in
12
conditions

Shankara Paneesha

Birmingham, ENG, GB 
Expertise in
12
conditions
Birmingham, ENG, GB 
OverviewLocationsClinical Research

Overview

Shankara Paneesha practices in Birmingham, United Kingdom. Paneesha is highly rated in 12 conditions, according to our data. Their top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), Chronic B-Cell Leukemia (CBCL), and Bone Marrow Transplant.

Their clinical research consists of co-authoring 52 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Birmingham, ENG, United Kingdom
Other Locations
Chippenham, ENG, United Kingdom
London, ENG, United Kingdom
Castle Hill Hospital
Kingston Upon Hull, ENG, United Kingdom
ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Radiation, Other
Study Phase: Not Applicable
A Single Arm Open Labeled Multicentre Phase 1b Dose Escalation Study of Carfilzomib Taken in Combination With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
A Single Arm Open Labeled Multicentre Phase 1b Dose Escalation Study of Carfilzomib Taken in Combination With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
Enrollment Status: Completed
Publish Date: April 15, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

52 Total Publications

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
Journal: The New England journal of medicine
Published: June 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Paneesha's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile